Circulation, Vol 52, 137-140, Copyright © 1975 by American Heart Association
SG Chrysant, K Nishiyama, PN Adamopoulos and ED Frohlich
Although available elsewhere, bethanidine remains under study in the U.S.
and its hemodynamic effects are unreported. Therefore, 29 patients with
moderately severe essential hypertension received one of four oral dose
levels (0.10, 0.25, 0.35, or 0.50 mg/kg) of the postganglionic
sympatholytic drug. Blood pressure was reduced only in the 14 patients
receiving the highest dose. This was demonstrated within three hours, first
by a significant postural hypotension (upright tilt: +14 before vs -19 mm
Hg after, P less than 0.001). This orthostatic hypotension effect was
associated with a greater fall in cardiac output (13 vs 22%, P less than
0.025) and a diminished reflective increase in total peripheral resistance
(19 vs 6%, P less than 0.01); an attenuated Valsalva maneuver overshoot in
the supine position was also observed (42 vs 10%, P less than 0.001). Eight
of these 14 patients demonstrated supine hypotension associated with either
reduced output and/or resistance. Hence, bethanidine is a rather rapidly
acting oral sympatholytic agent which reduces blood pressure by producing:
(1) decreasec venous return (especially in upright position), suggesting
venodilation; (2) arteriolar dilation (supine and upright) reducing
peripheral vascular resistance; and (3) attenuated cardiovascular
sympathetic reflective adjustments.
ARTICLES
Systemic hemodynamic effects of bethanidine in essential hypertension
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1975 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |